Comments Off on X4 Pharmaceuticals Presents Additional Positive Phase 2 Results for X4P 001 in WHIM Syndrome, Continues on Path to Initiation of Phase 3 Trial
CAMBRIDGE, MA – December 1, 2018 – X4 Pharmaceuticals, a
Comments Off on Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting
SAN DIEGO, Nov. 9, 2018 /PRNewswire/ — Mirati Therapeutics, Inc.
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok